The FDA Has Granted Fast Track Designation To Innate Pharma/Sanofi Partnered SAR'579 / IPH6101 For Hematological Malignancies
Portfolio Pulse from Benzinga Newsdesk
The FDA has granted Fast Track designation to Innate Pharma and Sanofi's partnered SAR'579 / IPH6101 for the treatment of hematological malignancies. This accelerates the development and review process for the drug.
June 08, 2023 | 8:25 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Innate Pharma's partnered drug with Sanofi, SAR'579 / IPH6101, receives FDA Fast Track designation for hematological malignancies.
The FDA Fast Track designation for Innate Pharma's partnered drug with Sanofi is a positive development for the company. It accelerates the development and review process, potentially leading to faster approval and market entry. This could positively impact Innate Pharma's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50
POSITIVE IMPACT
Sanofi's partnered drug with Innate Pharma, SAR'579 / IPH6101, receives FDA Fast Track designation for hematological malignancies.
The FDA Fast Track designation for Sanofi's partnered drug with Innate Pharma is a positive development for the company. It accelerates the development and review process, potentially leading to faster approval and market entry. This could positively impact Sanofi's stock price in the short term.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 50